December 10, 2016 1:04 AM ET

Biotechnology

Company Overview of Epizyme, Inc.

Company Overview

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. The company’s proprietary product platform creates small molecule inhibitors of enzymes known as histone methyltransferases (HMTs). Its lead product candidate includes tazemetostat, an inhibitor of the EZH2 HMT, which is in Phase II clinical study in adults with relapsed or refractory non-Hodgkin lymphoma; and in phase II study in adults and phase I study in children with certain genetically-defined solid tumors, as well as for the treatment of mesothelioma. The company is also developing additional programs, including a Phase I clinical trial of pinometostat, an inhibi...

400 Technology Square

4th Floor

Cambridge, MA 02139

United States

Founded in 2007

89 Employees

Phone:

617-229-5872

Fax:

617-349-0707

Key Executives for Epizyme, Inc.

Chief Executive Officer, President and Director
Age: 48
Total Annual Compensation: $293.5K
Chief Financial Officer, Executive Vice President of Finance & Administration and Treasurer
Age: 45
Total Annual Compensation: $500.8K
Chief Scientific Officer and President of Research
Age: 59
Total Annual Compensation: $595.0K
Chief Medical Officer and Executive Vice President
Age: 54
Total Annual Compensation: $163.7K
Compensation as of Fiscal Year 2015.

Epizyme, Inc. Key Developments

Epizyme, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016

Epizyme, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. For the third quarter, the company reported collaboration revenue of $6,584,000 against $358,000 a year ago. The increase was driven predominantly by the recognition of the $6.0 million milestone earned upon GlaxoSmithKline’s (GSK) initiation of patient dosing in a Phase 1 clinical trial of GSK3326595, a PRMT5 inhibitor invented by Epizyme and licensed to GSK. Loss from operations was $24,826,000 against $23,106,000 a year ago. Net loss was $24,336,000 or $0.42 per basic and diluted share against $23,065,000 or $0.56 per basic and diluted share a year ago. For the nine months period, the company reported collaboration revenue of $7,529,000 against $2,005,000 a year ago. Loss from operations was $76,341,000 against $110,268,000 a year ago. Net loss was $75,196,000 or $1.32 per basic and diluted share against $110,150,000 or $2.81 per basic and diluted share a year ago.

Epizyme, Inc. Enters into Two Cooperative Research and Development Agreements with the Cancer Therapy Evaluation Program of the National Cancer Institute

Epizyme, Inc. announced that it has entered into two Cooperative Research and Development Agreements (CRADAs) with the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). The CRADAs will evaluate tazemetostat, Epizyme's first-in-class EZH2 inhibitor, and pinometostat, the Company's first-in-class DOT1L inhibitor. Both investigational medicines target proteins implicated in the development and regulation of cancer. As part of the CRADA for tazemetostat, CTEP will collaborate with Epizyme in clinical trials to evaluate the safety and efficacy of tazemetostat in patients with hematologic malignancies and solid tumors. The initial NCI-sponsored study will evaluate tazemetostat in a phase 2 clinical trial in patients with ovarian cancer. External publications and Epizyme preclinical data indicate that inhibition of EZH2 could be beneficial in subsets of ovarian cancer. Under the second CRADA, the safety and efficacy of pinometostat will be evaluated in patients with acute leukemias. Initial studies will evaluate the combination of pinometostat with standard-of-care therapies or targeted agents in acute myeloid leukemia, acute lymphoid leukemia, or mixed lineage leukemia characterized by a rearrangement in the mixed lineage leukemia gene (MLL-r). Preclinical studies of pinometostat in MLL-r cell line models have shown synergy with chemotherapies, including acute leukemia standard-of-care agents and select targeted therapies. As part of both agreements, additional clinical trials will be considered.

Epizyme, Inc. to Report Q3, 2016 Results on Nov 03, 2016

Epizyme, Inc. announced that they will report Q3, 2016 results at 8:30 AM, US Eastern Standard Time on Nov 03, 2016

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Epizyme, Inc., please visit www.epizyme.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.